Flamel Technologies SA is a specialty pharmaceutical company with a long history of expertise in drug delivery. The acquisition of Éclat Pharmaceuticals LLC has created a more vertically integrated company, benefiting from greater development and commercial expertise, best in class drug delivery platforms and potential value creating catalysts.
Drug Delivery Platforms
Modified/Controlled Release of Solid Oral Drugs
Modified/Controlled Release of Liquid Oral Drugs
Abuse-Resistant Modified/Controlled Release Narcotics/Opioid Analgesics
Modified/Controlled Release of Injectable Drugs
Flamel Technologies currently markets Bloxiverz and Vazculep (FDA-approved products), and develops internally products using the Unapproved Marketed Drug strategy and products based on its drug delivery platforms, and products with partners.
As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.